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We investigated the effects of XPG His1104Asp polymorphism
(rs17655) on the risk of lung cancer and squamous cell carcinomas
of the oropharynx, larynx and esophagus (SCCOLE). This popula-
tion-based case-control study involves 611 new cases of lung can-
cer, 601 new cases of oropharyngeal, laryngeal and esophageal
cancers, and 1,040 cancer-free controls. The XPG polymorphism
was assayed by PCR-RFLP method for 497 lung cancer cases,
443 cases of oropharyngeal, laryngeal and esophageal cancers and
912 controls. Binary and polytomous unconditional logistic regres-
sion models were ﬁtted to assess the main effects and the effect
modiﬁcations between the polymorphism and environmental
exposures. With the adjustment for potential confounders, the
XPG Asp1104Asp genotype was inversely associated with lung
cancer (odds ratio [OR] 5 0.62, 95% conﬁdence limits [CL] 5
0.38, 1.0) and SCCOLE (OR 5 0.47, 95% CL 5 0.27, 0.82), with
the combined His1104His and His1104Asp genotypes as the refer-
ent. With subjects having genotype Asp1104Asp and no tobacco
smoking exposure as the common referent, the ORs on lung can-
cer were 13 (95% CL 5 4.4, 37) for heavy tobacco smoking (>20
pack-years), 1.9 (95% CL 5 0.78, 4.5) for having at least one copy
of 1104His, and 23 (95% CL 5 9.5, 56) for the joint effect, respec-
tively. Compared to non-smokers with the Asp1104Asp genotype,
the adjusted OR on SCCOLE for heavy smokers (>20 pack-years)
having at least one copy of 1104His was 8.0 (95% CL 5 2.7, 24).
Similarly, compared to non-drinkers with the Asp1104Asp geno-
type, the adjusted OR on SCCOLE for heavy drinkers (3 drinks/
day) with at least one copy of 1104His was 10 (95% CL 5 2.7, 38).
In conclusion, our study suggests that the XPG Asp1104Asp geno-
type may be associated with decreased susceptibility to lung can-
cer and SCCOLE.
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Various DNA alterations can be caused by exposure to carcino-
genic and cytotoxic compounds from environmental agents and
endogenous metabolites.1 Most of these alterations, if unrepaired,
may result in genetic instability, mutagenesis, and cell death.
DNA repair mechanisms are important for maintaining DNA
integrity and preventing oncogenesis. Nucleotide excision repair
(NER) can remove bulky adducts induced by environmental
agents such as ultraviolet irradiation, tobacco smoking, and diet-
ary factors. NER is one of the most important DNA repair path-
ways against tobacco-related carcinogenesis.2 It has been postu-
lated that the phenotype of DNA repair capacity varies in the gen-
eral population, and that individuals with suboptimal DNA repair
capacity are at an increased risk of developing various cancers.3
Genetic polymorphisms in the coding and regulatory sequences of
repair pathway components are among the major contributors to
the variation of DNA repair capacity, thereby modifying cancer
susceptibility.4
Xeroderma Pigmentosum Group G (XPG), one important
component of the NER pathway, encodes a structure-speciﬁc
endonuclease catalyzing 30 incision and involves the subsequent 50
incision by ERCC1-XPF heterodimer.5,6 It is also involved in the
stabilization of a pre-incision complex on the damaged DNA.7
XPG gene maps to chromosome 13q33.8 One common non-synon-
ymous single nucleotide polymorphism (SNP) in its coding region
has been identiﬁed, which causes the amino acid change of
His1104Asp (rs17655). The His1104Asp polymorphism locates in
the XPG C-terminus, which is required for the interactions
between XPG and other components of the NER pathway such as
TFIIH subunits.9 The His1104Asp amino acid change may inﬂu-
ence these protein-protein interactions and consequently predis-
pose individuals with the suboptimal variants to various cancers.
To our knowledge, there has been no study published on the
potential effect of the XPG codon 1104 polymorphism on the risk
of lung cancer or squamous cell carcinomas of the oropharynx,
larynx, and esophagus (SCCOLE) in the United States population.
We investigated the effects of the XPG His1104Asp polymor-
phism on the risk of developing lung cancer and SCCOLE in a
population-based case-control study. We also investigated poten-
tial modiﬁcations of tobacco- and alcohol-induced carcinogenesis
of the above-mentioned cancers by the polymorphism.
Material and methods
Study design and study subjects
This population-based case-control study comprised 611 new
cases of lung cancer, 601 new cases of oropharyngeal, laryngeal
and esophageal cancers (303 oral cancers, 100 pharyngeal cancers,
90 laryngeal cancers and 108 esophageal cancers), and 1,040 can-
cer-free controls. Histologically conﬁrmed new cases were
obtained by the rapid ascertainment system of the Cancer Surveil-
lance Program for Los Angeles County, which is administered by
the Keck School of Medicine and Norris Comprehensive Cancer
Center at the University of Southern California. The USC Cancer
Surveillance Program is the population-based cancer registry for
Los Angeles County, which has collected basic clinical and demo-
graphic information on all invasive cancers (except non-melanoma
skin cancer) diagnosed among residents of Los Angeles County
since 1972. Over 95% of cancer reports are histologically veriﬁed;
the remainder veriﬁed by MRI, CT scan or other diagnostic meth-
ods. Cases of oropharyngeal, laryngeal, esophageal, and lung can-
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cers were excluded if they had a previous diagnosis; this informa-
tion was determined from Cancer Surveillance Program records
and veriﬁed from cases’ self-reports in their interviews. To be eli-
gible as a potential control, an individual must not have had any
history of oropharyngeal, laryngeal, esophageal, or lung cancer.
Controls were identiﬁed by using a formal algorithm to take a cen-
sus of households in the neighborhood of the case, and matching
potentially available controls to the case by age (within 10-year
categories) and gender. All study subjects met the following crite-
ria: (i) be residents of Los Angeles County at time of diagnosis for
cases or at time of recruitment for controls; (ii) be 18–65 years of
age during the observation period, 1999–2004; and (iii) speak
either English or Spanish, or have translators available at home.
The recruitment rates were 39% (611 of 1,556) for eligible lung
cancer cases, 46% (601 of 1,301) for eligible oropharyngeal, lar-
yngeal and esophageal cancer cases and 79% (1,040 of 1,321) for
contacted eligible controls, respectively. We could not recruit
some eligible cases into our study due to the following reasons:
(i) the patients died before we contacted them (10% for orophar-
yngeal, laryngeal and esophageal cancers, 25% for lung cancer);
(ii) we could not contact the patients due to incorrect addresses
(18% for oropharyngeal, laryngeal and esophageal cancers, 14%
for lung cancer); (iii) the patients were too ill to get interviewed
(4% for oropharyngeal, laryngeal and esophageal cancers, 5% for
lung cancer); (iv) the patients were not willing to participate the
study (21% for oropharyngeal, laryngeal and esophageal cancers,
16% for lung cancer); and (v) the physicians refused our requests
to contact their patients (1% for both oropharyngeal, laryngeal and
esophageal cancers and lung cancer). In-person interviews were
conducted with each case and control using standardized question-
naires. Each interview was administered by specially trained staff
personnel and took about 45–60 min to complete. Both the case
and his or her matched control were interviewed by the same staff
member; and, to the extent possible, we matched the gender and
ethnicity of the subjects with the gender and ethnicity of their
interviewers. Self-reported information was collected on a variety
of factors known to affect, or might affect, the risk of investigated
cancers or that might otherwise be methodologically relevant to
the analysis. These factors include socio-demographic characteris-
tics, history of tobacco smoking, environmental tobacco smoking,
drug and alcohol use, occupational and environmental exposures,
selected clinical factors, diet and other behaviors. The lifetime
accumulated history of tobacco smoking and alcohol drinking for
study subjects was recorded in the questionnaires, which provided
us the information on age of onset, duration of exposures, intensity
of exposures, cumulative exposures and years of quitting before
diagnosis for cases or interview for controls. After the interview,
buccal swabs were collected for DNA extraction. A total of 1,986
buccal cell samples were collected from study subjects. The proto-
col was approved by the Institutional Review Boards of the
University of California at Los Angeles and the University of
Southern California. Informed consent was obtained from all
study subjects.
Genotype analysis
Buccal cells were collected using a standard protocol by brush-
ing the buccal mucosa, rinsing with mouthwash and expectorating
into a plastic container.10 Genomic DNA was subsequently
extracted from the buccal cells using a modiﬁed phenol-chloro-
form protocol.10 The XPG His1104Asp polymorphism was deter-
mined by a PCR-RFLP assay described by Jeon et al.11 Brieﬂy,
100 ng of the DNA sample was ampliﬁed using 0.2 lM primers
(50-GACCTGCCTCTCAGAATCATC-30 and 50-CCTCGCACG-
TCTTAGTTTCC-30), 20 lM dNTP, 1 U Taq DNA polymerase
(Promega, Madison, WI), and 1.5 mM MgCl2 in a total volume of
20 ll. Thermal cycling was carried out under the following condi-
tions: initial denaturation at 95C for 5 min; subsequently 35
cycles of 94C for 30 sec, 60C for 45 sec and 72C for 45 sec;
and a ﬁnal elongation step of 72C for 5min. The PCR product
(271 bp fragment) was then digested for 6 hr with 10 U of NlaIII
(New England Biolabs Inc., Beverly, MA) at 37C and followed
by resolution process on 4% agarose gel stained with ethidium
bromide. The His/His genotype was determined by the presence of
2 bands at 227 and 44 bp, the Asp/Asp genotype by the presence
of an uncut 271 bp band, and the heterozygous His/Asp genotype
by the presence of three bands at 271, 227 and 44 bp. Standard lab-
oratory procedure was followed in the study. The laboratory per-
sonnel were blinded on the disease status of study subjects. Nega-
tive control (without sample DNA in the reaction system) was
applied in the PCR step to rule out potential contamination. PCR
products were checked for validity according to their relative posi-
tion to the markers (100 bp DNA ladder). Both positive (his1104
homozygote) and negative (Asp1104 homozygote) controls were
applied in the digestion to ensure that the samples were fully
digested by the enzyme and to rule out potential contamination.
Independent repetition of genotyping in a randomly selected sam-
ple (n 5 120) produced the same results. The XPG polymorphism
was successfully genotyped for 497 lung cancer cases, 443 cases of
oropharyngeal, laryngeal and esophageal cancers and 912 controls.
The genotyping success rate was 93.2% (1,852 of 1,986 samples).
Statistical analysis
We used the goodness-of-ﬁt v2 to test whether the XPG geno-
types were in the Hardy-Weinberg equilibrium. To increase the
precision of estimation and the power to test hypotheses, we used
binary and polytomous unconditional logistic regression models
including terms for the matching factors age and gender, which
allowed us to include cases with no matched control.12 Odds ratios
(ORs) and 95% conﬁdence limits (CLs) were calculated with and
without adjustment for potential confounders, respectively. The
potential confounders included age, gender (male/female), ethnic
origin/ethnicity (Caucasian, Mexican-American, African-Ameri-
can, Asian-American, other), educational level, alcohol drinking
and tobacco smoking. To minimize age confounding, age was
controlled in ﬁne categories (under 34, 35–36, 37–38, 39–40, 41–
42, 43–44, 45–46, 47–48, 49–50, 51–52, 53–54, 55–56, 57–58,
59–62), and we excluded controls that were more than 3 years
younger than the youngest case or 3 years older than the oldest
case from the analysis. The age ranges were 32–59 for lung cancer
cases and 20–59 for oropharyngeal, laryngeal and esophageal can-
cer cases, respectively. Overall 11 controls were excluded from
the analysis of lung cancer and one control was excluded from the
analysis of oropharyngeal, laryngeal and esophageal cancers. Edu-
cational level (years of schooling), tobacco smoking (pack-years)
and alcohol consumption (drinks/day * years) were controlled as
continuous variables.
We initially explored the main effect of the XPG polymorphism
in two different ways by assuming either additive or dominant
model. We primarily report the results on the XPG polymorphism
with subjects having at least one allele of 1104His as the referent
because our data supported that 1104His allele might dominate
1104Asp allele. Modiﬁcation of tobacco smoking and alcohol
effects by the polymorphism was also investigated. Heavy smok-
ing was deﬁned as smoking more than 20 pack-years, and heavy
drinking was deﬁned as consuming 3 drinks/day or more. All data
analyses were conducted in SAS V8.2 (SAS Institute, Cary, NC).
p-Values are two-sided.
Results
Among the lung cancer cases, there were 95 diagnosed as squa-
mous cell carcinoma, 297 as adenocarcinoma, 115 as large-cell
lung cancer, and 75 as small-cell lung cancer. Among oropharyng-
eal, laryngeal and esophageal cancer cases, 497 (300 oral cancers,
75 pharyngeal cancers, 90 laryngeal cancers and 32 esophageal
cancers) were diagnosed as squamous cell carcinoma. The distri-
butions of demographic characteristics and potential risk factors
are summarized in Table I. The ORs for age and gender were not
presented because the estimates from regression models are not
valid for these two matching variables. Tobacco smoking was the
715XPG POLYMORPHISM, LUNG CANCER AND SCCOLE
strongest risk factor for lung cancer with an extremely increased
risk among subjects who smoked >40 pack-years (OR 5 22, 95%
CL 5 14, 34). Both alcohol drinking (3 drinks/day vs.
<3 drinks/day: OR 5 1.9, 95% CL 5 1.4, 2.7) and tobacco smok-
ing (>40 pack-years vs. nonsmoking: OR 5 3.5, 95% CL 5 2.3,
5.3) were strongly associated with oropharyngeal, laryngeal and
esophageal cancers.
Genotyping data on the XPG His1104Asp polymorphism were
available for 497 lung cancer cases, 443 oropharyngeal, laryngeal
and esophageal cancer cases (202 oral, 74 pharyngeal, 73 laryng-
eal and 94 esophageal cancer cases), and 912 controls. Overall,
the allele frequencies were 72% for G allele (His) and 28% for C
allele (Asp) in the control group, which were very similar to those
reported by the Cancer Genome Anatomy Project.8 The ethnic
origin/ethnicity-speciﬁc frequencies for C allele were 22% for
Caucasians, 34% for Mexican-Americans, 48% for African-
Americans, and 49% for Asian-Americans. No departures from
Hardy-Weinberg equilibrium were detected for the overall allelic
frequency distribution (p 5 0.27) and the ethnic origin/ethnicity-
speciﬁc allelic frequency distributions (p 5 0.37 for Caucasians;
p 5 0.058 for Mexican-Americans; p 5 0.35 for African-Ameri-
cans; p 5 0.41 for Asian-Americans). Overall, the Asp1104Asp
genotype was slightly under-represented in both the oropharyng-
eal, laryngeal and esophageal cancer group (7.9%) and the lung
cancer group (8.3%), compared to the controls (8.8%).
With the adjustment for age, gender, ethnic origin/ethnicity,
educational level and pack-years of tobacco smoking, the
Asp1104Asp genotype was associated with a slight decrease in the
risk of lung cancer (OR 5 0.62, 95% CL 5 0.38, 1.0) with the
combined His1104His and His1104Asp genotypes as the referent
(Table II). Stratiﬁed analyses displayed consistent negative associ-
ations for Caucasians (OR 5 0.47, 95% CL 5 0.18, 1.2), Mexi-
can-Americans (OR 5 0.41, 95% CL 5 0.11, 1.6), African-Amer-
icans (OR 5 0.55, 95% CL 5 0.18, 1.7), and Asian-Americans
(OR 5 0.69, 95% CL 5 0.23, 2.0). Polytomous logistic regression
exhibited inverse associations of Asp1104Asp genotype with
adenocarcinoma (OR 5 0.69, 95% CL 5 0.39, 1.2), small-cell
lung cancer (OR 5 0.55, 95% CL5 0.18, 1.7), and large-cell lung
cancer (OR 5 0.31, 95% CL 5 0.10, 0.92), but not with squamous
cell carcinoma (OR5 1.0, 95% CL5 0.45, 2.3).
With the adjustment for age, gender, ethnic origin/ethnicity,
educational level, alcohol drinking and pack-years of tobacco
smoking, the Asp1104Asp genotype was associated with a
decreased risk of oropharyngeal, laryngeal and esophageal cancers
with the combined His1104His and His1104Asp genotypes as the
reference group (OR 5 0.67, 95% CL 5 0.42, 1.1) (Table III).
Genotyping data was available for 355 SCCOLE cases (200 for
oral cavity, 56 for pharynx, 73 for larynx and 26 for esophagus).
The inverse association between the Asp1104Asp genotype and
SCCOLE was stronger (OR 5 0.47, 95% CL 5 0.27, 0.82). Poly-
tomous logistic regression exhibited inverse associations with squ-
amous cell carcinoma of the oral cavity (OR 5 0.48, 95% CL 5
0.24, 0.96), pharynx (OR 5 0.44, 95% CL 5 0.14, 1.4), larynx
(OR 5 0.46, 95% CL 5 0.16, 1.3), and esophagus (OR 5 0.35,
95% CL 5 0.07, 1.7). Stratiﬁed analyses exhibited a tendency
toward negative associations for Caucasians (OR 5 0.55, 95%
CL 5 0.20, 1.5), African-Americans (OR 5 0.51, 95% CL 5
0.15, 1.8) and Asian-Americans (OR 5 0.06, 95% CL 5 0.01,
0.44). Association for Mexican-Americans could not be assessed
due to limited numbers.
Table IV summarizes the effect modiﬁcation of tobacco smok-
ing on lung cancer and the consumption of tobacco and alcohol on
SCCOLE by the XPG polymorphism. With subjects having geno-
type Asp1104Asp and no tobacco smoking exposure as the com-
TABLE I – DISTRIBUTIONS OF DEMOGRAPHIC CHARACTERISTICS AND POTENTIAL RISK FACTORS
Key variable
Oropharyngeal, laryngeal and esophageal cancers Lung cancer
Controls N (%) Cases N (%) Adjusted OR (95% CL)1 Controls N (%) Cases N (%) Adjusted OR (95% CL)1
Age2,3
17–34 51 (4.9) 32 (5.3) — 41 (4.0) 4 (0.6) —
35–44 171 (16.5) 77 (12.8) — 171 (16.6) 57 (9.3) —
45–54 499 (48.0) 267 (44.4) — 499 (48.5) 301 (49.3) —
>54 318 (30.6) 225 (37.5) — 318 (30.9) 249 (40.8) —
Gender2
Female 416 (40.0) 147 (24.5) — 413 (40.1) 308 (50.4) —
Male 623 (60.0) 454 (75.5) — 616 (59.9) 303 (49.6) —
Ethnic origin/ethnicity
Caucasian 634 (61.1) 341 (56.9) 1.0 628 (61.1) 359 (58.9) 1.0
Mexican 149 (14.3) 70 (11.7) 0.53 (0.35, 0.81) 148 (14.4) 53 (8.7) 0.91 (0.57, 1.5)
African 102 (9.8) 69 (11.5) 1.1 (0.78, 1.6) 102 (9.9) 96 (15.7) 2.0 (1.4, 2.9)
Asian 62 (6.0) 64 (10.7) 2.7 (1.8, 4.1) 60 (5.8) 70 (11.5) 4.7 (3.1, 7.2)
Other 91 (8.8) 55 (9.2) 0.95 (0.63, 1.4) 90 (8.8) 32 (5.2) 0.78 (0.47, 1.3)
Missing 1 2 1 1
Education (years of schooling)
0–12 299 (28.8) 273 (45.4) 1.0 299 (29.1) 265 (43.4) 1.0
13–16 481 (46.3) 259 (43.1) 0.63 (0.48, 0.82) 471 (45.8) 275 (45.0) 0.79 (0.60, 1.0)
>16 258 (24.9) 69 (11.5) 0.36 (0.25, 0.52) 258 (25.1) 71 (11.6) 0.55 (0.37, 0.80)
Missing 1 0 1 0
ptrend < 0.0001 ptrend 5 0.0021
Alcohol drinking (drinks/day)
0–2 946 (91.4) 446 (74.5) 1.0 937 (91.3) 520 (85.3) 1.0
3 89 (8.6) 153 (25.5) 1.9 (1.4, 2.7) 89 (8.7) 90 (14.7) 0.89 (0.59, 1.3)
Missing 4 2 3 1
Pack-years of tobacco smoking
Never 491 (47.3) 182 (30.3) 1.0 484 (47.1) 110 (18.0) 1.0
1–20 353 (34.0) 147 (24.4) 0.97 (0.73, 1.3) 350 (34.1) 102 (16.7) 1.4 (1.0, 1.9)
21–40 136 (13.1) 146 (24.3) 2.0 (1.4, 2.8) 136 (13.2) 202 (33.1) 7.9 (5.6, 11)
>40 58 (5.6) 126 (21.0) 3.5 (2.3, 5.3) 58 (5.6) 197 (32.2) 22 (14, 34)
Missing 1 0 1 0
ptrend < 0.0001 ptrend < 0.0001
1Adjusted for the variables listed in Table I.–2Odds ratios (ORs) are not presented because age and gender are matching variables and their OR
estimated by the regression models are not valid.–3Age was controlled in ﬁne categories although it was presented here in 4 broad categories.
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mon referent, the odds ratios on lung cancer risk were 13 (95%
CL 5 4.4, 37) for heavy tobacco smoking (>20 pack-years), 1.9
(95% CL 5 0.78, 4.5) for having at least one copy of 1104His,
and 23 (95% CL 5 9.5, 56) for exposure to both conditions,
respectively. The upward departure from additivity (23 2 13 2
1.9 1 1 5 9.1, 95% CL 5 22.9, 21.7) suggests that the polymor-
phism might act synergistically with tobacco smoking on lung car-
cinogenesis among heavy smokers. Compared to non-smokers
with the Asp1104Asp genotype, the adjusted odds ratio on
SCCOLE for heavy smokers (>20 pack-years) having at least one
copy of 1104His was 8.0 (95% CL 5 2.7, 24). Similarly, com-
pared to non-drinkers with the Asp1104Asp genotype, the adjusted
OR on SCCOLE for heavy drinkers (3 drinks/day) with at least
one copy of 1104His was 10 (95% CL 5 2.7, 38). Modiﬁcation of
tobacco and alcohol effects on SCCOLE by the polymorphism
among heavy consumers could not be precisely assessed due to
limited numbers (smoking: 8.0 2 3.9 2 3.6 1 1 5 1.5, 95%
CL 5 22.3, 5.4; alcohol: 102 3.9 2 4.4 1 1 5 2.7, 95% CL 5
23.4, 8.7). When compared to non- or light-consumers of tobacco
(<5 20 pack-years) and alcohol (<3 drinks/day) with the
Asp1104Asp genotype, subjects with heavy exposures to tobacco
(>20 pack-years) and alcohol (3 drinks/day) and with at least
one copy of 1104His were at an extremely increased risk of
SCCOLE (OR5 18, 95% CL 5 7.5, 45) (Table V).
Discussion
The XPG gene encodes a 133 kDa acidic protein with an open
reading frame of 1186 amino acids.13 It consists of 2 non-synony-
mous SNPs (His1104Asp, rs17655; Ser529Cys, rs2227869), one
synonymous SNP (His46His, rs1047768) and 2 SNPs in untrans-
lated region (rs2296148; rs873601), and more than 35 intron SNPs
with their heterozygosity 9.5%. Our study focused on the non-
synonymous SNP His1104Asp (rs17655), which has been vali-
dated by National Center for Biotechnology Information SNP
database, Cancer Genome Anatomy SNP database, and Hap-Map
project. Another non-synonymous SNP, Ser529Cys (rs2227869),
was not studied because it is uncommon in the general population
(reported heterozygosity <10%) and our study does not have
enough power to detect the association, if there is any. Decreased
expression of XPG in lymphocytes has been associated with an
increased risk of lung cancer and squamous cell carcinoma of head
and neck.14,15 We found that the XPG Asp1104Asp genotype was
associated with a decreased risk of developing lung cancer and
SCCOLE. The results for lung cancer were consistent with that
reported by a Korean Study, which found the Asp1104Asp geno-
type was associated with a 46% decreased risk of lung cancer
compared to the combination of His1104His and His1104Asp
genotypes (OR 5 0.54, 95%CL 5 0.37, 0.80).11 The His1104Asp
polymorphism locates in the XPG C-terminus, which is required
for the interactions between XPG and TFIIH subunits in the NER
pathway.9 The amino acid change from acidic Aspartic Acid
to basic Histidine may change the XPG protein structure and
therefore inﬂuence the protein-protein interactions and the stabil-
ity of the pre-incision complex. The potential harmful effect
incurred by 1104His is also supported by computational function
analyses, as the SIFT (sorting intolerant from tolerant) program
predicts the amino acid change from aspartic acid to histidine
‘‘intolerant’’ and PolyPhen predicts the amino acid change ‘‘pos-
sibly damaging’’.16
We found a negative association of the XPG Asp1104Asp geno-
type with lung adenocarcinoma, small-cell lung cancer, and large-
cell lung cancer, suggestive of protective effects, but not with lung
squamous cell carcinoma. This histological difference might be
TABLE II – ASSOCIATION BETWEEN THE XPG POLYMORPHISM AND THE RISK OF LUNG CANCER
XPG Cases N (%) Controls N (%)
OR (95% CL)
Crude Adjusted1
All lung cancer cases
His/His 244 (49.1) 468 (51.9) 1.0 1.0
His/Asp 212 (42.7) 356 (39.5) 1.1 (0.91, 1.4) 1.1 (0.80, 1.4)
Asp/Asp 41 (8.2) 78 (8.6) 1.0 (0.67, 1.5) 0.65 (0.39, 1.1)
ptrend 5 0.51 ptrend5 0.36
His/His 1 His/Asp 456 (91.8) 824 (91.4) 1.0 1.0
Asp/Asp 41 (8.2) 78 (8.6) 0.95 (0.64, 1.4) 0.62 (0.38, 1.0)
Ethnic origin/ethnicity-speciﬁc
Caucasian
His/His 1 His/Asp 276 (95.5) 532 (95.7) 1.0 1.0
Asp/Asp 13 (4.5) 24 (4.3) 1.0 (0.52, 2.1) 0.47 (0.18, 1.2)
Mexican-American
His/His 1 His/Asp 41 (91.1) 116 (85.3) 1.0 1.0
Asp/Asp 4 (8.9) 20 (14.7) 0.57 (0.18, 1.8) 0.41 (0.11, 1.6)
African-American
His/His 1 His/Asp 69 (85.2) 60 (79.0) 1.0 1.0
Asp/Asp 12 (14.8) 16 (21.0) 0.65 (0.29, 1.5) 0.55 (0.18, 1.7)
Asian-American
His/His 1 His/Asp 40 (78.4) 37 (74.0) 1.0 1.0
Asp/Asp 11 (21.6) 13 (26.0) 0.78 (0.31, 2.0) 0.69 (0.23, 2.0)
Histology-speciﬁc
Adenocarcinoma
His/His 1 His/Asp 221 (91.3) 824 (91.4) 1.0 1.0
Asp/Asp 21 (8.7) 78 (8.6) 1.0 (0.61, 1.7) 0.69 (0.39, 1.2)
Squamous cell carcinoma
His/His 1 His/Asp 68 (86.1) 824 (91.4) 1.0 1.0
Asp/Asp 11 (13.9) 78 (8.6) 1.7 (0.87, 3.4) 1.0 (0.45, 2.3)
Small-cell lung cancer
His/His 1 His/Asp 60 (93.7) 824 (91.4) 1.0 1.0
Asp/Asp 4 (6.3) 78 (8.6) 0.70 (0.25, 2.0) 0.55 (0.18, 1.7)
Large-cell lung cancer
His/His 1 His/Asp 85 (95.5) 824 (91.4) 1.0 1.0
Asp/Asp 4 (4.5) 78 (8.6) 0.50 (0.18, 1.4) 0.31 (0.10, 0.92)
1Adjusted for age, gender, ethnic origin/ethnicity, educational level and pack-years of tobacco smoking.
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TABLE III – ASSOCIATION BETWEEN THE XPG POLYMORPHISM AND THE RISK OF OROPHARYNGEAL, LARYNGEAL AND ESOPHAGEAL CANCERS
XPG Cases N (%) Controls N (%)
OR (95% CL)
Crude Adjusted1
All oropharyngeal, laryngeal and esophageal cancer cases
His/His 214 (48.3) 474 (52.0) 1.0 1.0
His/Asp 194 (43.8) 357 (39.2) 1.2 (0.95, 1.5) 1.1 (0.85, 1.5)
Asp/Asp 35 (7.9) 80 (8.8) 0.97 (0.63, 1.5) 0.71 (0.43, 1.2)
ptrend5 0.45 ptrend5 0.61
His/His 1 His/Asp 408 (92.1) 831 (91.2) 1.0 1.0
Asp/Asp 35 (7.9) 80 (8.8) 0.89 (0.59, 1.3) 0.67 (0.42, 1.1)
Squamous cell carcinomas of the oropharynx, larynx and esophagus (SCCOLE)
His/His 1 His/Asp 333 (93.8) 831 (91.2) 1.0 1.0
Asp/Asp 22 (6.2) 80 (8.8) 0.69 (0.42, 1.1) 0.47 (0.27, 0.82)
Ethnic origin/ethnicity-speciﬁc (SCCOLE)
Caucasian
His/His 1 His/Asp 200 (97.1) 537 (95.7) 1.0 1.0
Asp/Asp 6 (2.9) 24 (4.3) 0.67 (0.27, 1.7) 0.55 (0.20, 1.5)
Mexican-American2
His/His 1 His/Asp 47 (100.0) 116 (84.7) 1.0 1.0
Asp/Asp 0 (0.0) 21 (15.3) — —
African-American
His/His 1 His/Asp 35 (81.4) 60 (79.0) 1.0 1.0
Asp/Asp 8 (18.6) 16 (21.0) 0.86 (0.33, 2.2) 0.51 (0.15, 1.8)
Asian-American
His/His 1 His/Asp 27 (84.4) 38 (73.1) 1.0 1.0
Asp/Asp 5 (15.6) 14 (26.9) 0.50 (0.16, 1.6) 0.06 (0.01, 0.44)
Site-speciﬁc (SCCOLE)
Oral cavity
His/His 1 His/Asp 189 (94.5) 831 (91.2) 1.0 1.0
Asp/Asp 11 (5.5) 80 (8.8) 0.61 (0.32, 1.2) 0.48 (0.24, 0.96)
Pharynx
His/His 1 His/Asp 52 (92.9) 831 (91.2) 1.0 1.0
Asp/Asp 4 (7.1) 80 (8.8) 0.80 (0.28, 2.3) 0.44 (0.14, 1.4)
Larynx
His/His 1 His/Asp 68 (93.1) 831 (91.2) 1.0 1.0
Asp/Asp 5 (6.9) 80 (8.8) 0.76 (0.30, 1.9) 0.46 (0.16, 1.3)
Esophagus
His/His 1 His/Asp 24 (92.3) 831 (91.2) 1.0 1.0
Asp/Asp 2 (7.7) 80 (8.8) 0.87 (0.20, 3.7) 0.35 (0.07, 1.7)
1Adjusted for age, gender, ethnic origin/ethnicity, educational level, pack-years of tobacco smoking and alcohol drinking.–2The association
could not be assessed because no cases had Asp1104Asp genotype.
TABLE IV – EFFECT MODIFICATION OF TOBACCO SMOKING AND ALCOHOL DRINKING BY THE XPG POLYMORPHISM
Variable 1 Variable 2 Cases N (%) Controls N (%) Adjusted OR (95% CL)
Lung cancer1
Tobacco XPG
Never Asp/Asp 8 (1.6) 42 (4.7) 1.0
1-20 Pack-years Asp/Asp 8 (1.6) 19 (2.1) 2.4 (0.70, 8.1)
>20 Pack-years Asp/Asp 25 (5.0) 17 (1.9) 13 (4.4, 37)
Never His/His 1 His/Asp 79 (15.9) 386 (42.8) 1.9 (0.78, 4.5)
1-20 Pack-years His/His 1 His/Asp 71 (14.3) 288 (31.9) 2.2 (0.91, 5.3)
>20 Pack-years His/His 1 His/Asp 306 (61.6) 150 (16.6) 23 (9.5, 56)
SCCOLE2
Tobacco XPG
Never Asp/Asp 4 (1.1) 43 (4.7) 1.0
1-20 Pack-years Asp/Asp 5 (1.4) 20 (2.2) 2.2 (0.51, 9.6)
>20 Pack-years Asp/Asp 13 (3.7) 17 (1.9) 3.8 (1.0, 14)
Never His/His 1 His/Asp 100 (28.2) 391 (42.9) 3.6 (1.2, 11)
1-20 Pack-years His/His 1 His/Asp 80 (22.5) 290 (31.8) 3.2 (1.1, 9.5)
>20 Pack-years His/His 1 His/Asp 153 (43.1) 150 (16.5) 8.0 (2.7, 24)
SCCOLE3
Alcohol XPG
Never Asp/Asp 3 (0.9) 31 (3.4) 1.0
1-2 Drinks/day Asp/Asp 12 (3.4) 39 (4.3) 2.9 (0.70, 12)
3 Drinks/day Asp/Asp 7 (2.0) 10 (1.1) 3.9 (0.76, 21)
Never His/His 1 His/Asp 55 (15.5) 192 (21.1) 4.4 (1.2, 16)
1-2 Drinks/day His/His 1 His/Asp 184 (52.0) 568 (62.5) 4.4 (1.2, 16)
3 Drinks/day His/His 1 His/Asp 93 (26.2) 69 (7.6) 10 (2.7, 38)
1Adjusted for age, gender, ethnic origin/ethnicity and educational level.–2Adjusted for age, gender, ethnic origin/ethnicity, educational level
and alcohol drinking.–3Adjusted for age, gender, ethnic origin/ethnicity, educational level and tobacco smoking.
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due to chance or might be attributable to the etiologic difference
among these four subtypes of lung cancer. Experimental data has
suggested that tobacco polycyclic aromatic hydrocarbons (PAH)
predominantly induce lung squamous cell carcinoma; whereas
tobacco-speciﬁc nitrosamines predominantly induce lung adeno-
carcinoma.17,18 It has been proposed that the decreasing incidence
of lung squamous cell carcinoma over time might have been due
to the reduced exposure of the central bronchi to tobacco PAH,
and that the marked rise in lung adenocarcinoma might have parti-
ally resulted from an increased exposure of peripheral lung to
tobacco-speciﬁc nitrosamines.19 Unfortunately, tobacco-speciﬁc
chemicals involved in the large-cell and small-cell lung cancers
have not been very well documented. Nevertheless, it is possible
that these four subtypes of lung cancer may be caused by different
initiating or promoting agents found in tobacco and other environ-
mental factors. The XPG polymorphism may have differential
repair efﬁciency on different chemical-induced DNA adducts and
consequently have differential protective effects against different
histological types of lung cancer.
Interestingly, we found the XPG Asp1104Asp genotype nega-
tively associated with SCCOLE, although we detected no associa-
tion between the genotype and lung squamous cell carcinoma.
This seeming contradiction might be due to chance or might be
due to the fact that lung squamous cell carcinoma is different from
SCCOLE etiologically and that the XPG polymorphism has differ-
ential modifying effects on different chemical-induced carcino-
genesis. Alcohol drinking is a well-established risk factor for
SCCOLE, but not a risk factor for lung cancer.20 There are at least
two lines of evidence supporting the possibility that the NER path-
way is involved in alcohol-related carcinogenesis. First, alcohol
consumption can generate lipid peroxidation products such as
malondialdehyde (MDA) that is highly mutagenic and carcino-
genic.21 MDA can interact with DNA to form MDA-DNA
adducts, which can be repaired via the NER pathway.22 Second,
the NER pathway can remove certain types of small oxidative
DNA lesions induced by chronic alcohol consumption.21,23 The
XPG polymorphism may inﬂuence the capacity of the NER path-
way to repair alcohol-induced DNA lesions. Furthermore, recent
studies have showed that XPG contributes to base excision repair
as it can stimulate binding of HsNth1 to damaged DNA and
increases glycosylase/AP lyase activity.24,25 Therefore, the XPG
polymorphism may inﬂuence the efﬁciency of the base excision
repair pathway to repair the damage due to reactive oxygen spe-
cies generated by alcohol consumption. In summary, the different
associations of the XPG polymorphism with lung squamous cell
carcinoma and SCCOLE might be attributable to the etiologic dif-
ference between these two diseases and the differential repair
capacity of the XPG polymorphism on alcohol and tobacco-
induced carcinogenesis.
Our study is however subject to several limitations. Non-partici-
pation of certain cases and controls and unwillingness of some
recruited cases and controls to provide buccal cells might lead
to potential selection bias. Only 42% (1,212 of 2,857) of eligible
cancer patients identiﬁed by the tumor registry system were
recruited into the study. By contrast, a much higher fraction (79%)
of contacted controls participated in the study. A large proportion
but not all of this difference was due to death of cases before inter-
view. Eighty-eight percent (88%) of the participants donated buc-
cal cells. In order for bias to occur, participation among eligible
cases would have to be associated with exposures such as XPG
genotypes, and the associations would have to differ between
potential cases and controls. Both conditions occurring to the
extent needed to produce appreciable bias seem unlikely because
genotypes are neither known to study subjects nor associated with
uncontrolled factors that would differentially affect participation.
In addition, we found similar distributions on age, gender, alcohol
consumption and tobacco smoking between the subjects who
donated buccal cells and those who did not. Ten percent of eligible
oropharyngeal, laryngeal and esophageal cancer cases and 25% of
eligible lung cancer cases (20% for adenocarcinoma, 26% for squ-
amous cell carcinoma, 24% for small-cell lung cancer and 29%
for large-cell lung cancer) died before they could be recruited.
Selective-survival bias could have occurred if the XPG polymor-
phism were a prognostic factor for the above-mentioned cancers.
Unfortunately, we could not assess the direction and magnitude of
the potential selective-survival bias due to the lack of studies
investigating the effect of the polymorphism on the prognosis of
the above-mentioned cancers. Exposure misclassiﬁcation might
exist due to the retrospective nature of the measurements. Recall
bias may exist because cases and controls may differentially recall
certain exposures such as smoking history. Using the USC Cancer
Surveillance Program as the sources of cases, empirical evidence
from a previous case-control study on lung cancer suggested the
effect of tobacco use is estimated with little or no bias.26 Further-
more, there should be only minimal bias in misclassiﬁcation of
XPG genotypes because they were assayed by standard laboratory
protocols and all the laboratory researchers were blinded on the
disease status of study subjects. Last, residual confounding might
exist when evaluating the main effects and interactions, although to
ensure against this we adjusted the well-documented risk factors.
Strengths of our study include a relatively large sample size, a
population-based study design, and extensive relevant question-
naire data. In conclusion, we found that the XPG Asp1104Asp
genotype was negatively associated with lung cancer and
SCCOLE, suggesting protective effects on these cancers. We also
found some suggestion that the genotype synergistically modiﬁes
the effect of tobacco use on lung cancer risk.
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TABLE V – JOINT EFFECT OF TOBACCO SMOKING, ALCOHOL DRINKING AND XPG POLYMORPHISM ON THE RISK OF SCCOLE
Smoking (pack-years) Alcohol (drinks/day) XPG Cases N (%) Controls N (%) Adjusted OR (95% CL)1
<520 <3 Asp/Asp 8 (2.2) 60 (6.6) 1.0
<520 <3 His/His 1 His/Asp 158 (44.6) 641 (70.5) 2.6 (1.2, 5.8)
<520 3 Asp/Asp 1 (0.30) 3 (0.3) 3.4 (0.29, 40)
<520 3 His/His 1 His/Asp 23 (6.5) 39 (4.3) 4.6 (1.8, 12)
>20 <3 Asp/Asp 7 (2.0) 10 (1.1) 4.2 (1.2, 15)
>20 <3 His/His 1 His/Asp 81 (22.9) 119 (13.1) 5.7 (2.5, 13)
>20 3 Asp/Asp 6 (1.7) 7 (0.80) 5.3 (1.3, 21)
>20 3 His/His 1 His/Asp 70 (19.8) 30 (3.3) 18 (7.5, 45)
1Adjusted for age, gencer, ethnic origin/ethnicity and educational level.
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